Foresite closes second fund with $300 million

Foresite Capital Management closed Foresite Capital Fund II with $300 million. The firm, which closed its first fund with $100 million in January 2013, invests $10-$100 million in late-stage companies across the therapeutic, diagnostic and device and services sectors. The firm's portfolio includes pain company AcelRx Pharmaceuticals Inc.(NASDAQ:ACRX) and cancer company Puma Biotechnology Inc. (NYSE:PBYI) (see BioCentury, April 30, 2012). ...